Guinea: Usage of Ebola vaccine proves 100% success

Guinea: Usage of Ebola vaccine proves 100% success


Background of the disease

Ebola virus disease, also Ebola hemorrhagic fever, or simply Ebola, is a disease of humans and other primates caused by ebolaviruses.

Signs and symptoms

They typically start between two days to three weeks after the virus gets along a fever, sore throat, muscular pain, and headaches. Then, vomiting, diarrhea and rash usually follow, along with decreased function of the liver and kidneys. At this time some people begin to bleed both internally and externally.

The disease has a high risk of death, killing between 25 and 90 percent of those infected, with an average of about 50%. This is often due to low blood pressure from fluid loss, and typically follows six to sixteen days after symptoms appear.

There have been a total of 27,748 cases of Ebola in Guinea, Liberia and Sierra Leone up to 26 July 2015, with 11,279 reported deaths, although the outcome of many cases is unknown and the toll will be significantly higher. by the end of that week, there were just four new cases in Guinea and three in Sierra Leone.

A vaccine against this disease has shown almost 100% successful results during tests that had been conducted over 4000 patients and as per experts claim the vaccine is likely to bring the West African epidemic to an end.

Among the 2,014 people vaccinated immediately, there were no cases of Ebola from 10 days after vaccination – allowing time for immunity to develop.

Scientists, doctors, donors and drug companies collaborated to race the vaccine through a process that usually takes more than a decade in a year time span.

According to Børge Brende, the foreign minister of Norway, who helped fund the trial:

“Having seen the devastating effects of Ebola on communities and even whole countries with my own eyes, I am very encouraged by today’s news.”

Previous articleMany Facebook users use ‘haha’ instead of ‘Lolz’
Next articleJ.K Rowling is world’s first billionaire author

I cover technology, utilities and biotechnology for Markets Morning, and I help out occasionally with other industry sectors. I’ve written about investment and personal finance topics for more than 20 years from a lowly copywriter to editor-in-chief, so I’ve done a little bit of everything. For what it’s worth, I have a BA from Duke University and an MBA from Rollins College. I’m married with one daughter, and that’s worth more than everything else put together.